ObsEva SA

Equities

OBSN

CH1260041939

Biotechnology & Medical Research

End-of-day quote Swiss Exchange Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.006 ^CHF	+36.36%		+20.00%	-83.15%

Apr. 03	ObsEva to Delist from the SIX Swiss Exchange	MT
Mar. 20	ObsEva SA Announces to Wind-Down the Operations	CI

ObsEva SA announced that it expects to receive CHF 1.54 million in funding from ObsEva USA Inc.

December 07, 2022

ObsEva SA announced a private placement of 20,000,000 common shares at an issue price of 1/13 of a Swiss Franc (CHF 0.077) per share for gross proceeds of CHF 1,540,000 on December 8, 2022. The transaction included participation from by its 100% wholly owned subsidiary, Obseva Usa, Inc. The transaction has been approved by the board of directors of the company.

Latest news about ObsEva SA

ObsEva to Delist from the SIX Swiss Exchange	Apr. 03	MT
ObsEva SA Announces to Wind-Down the Operations	Mar. 19	CI
ObsEva SA Announces Catarina Edfjäll to Step Down from the Board	Mar. 19	CI
ObsEva to Wind Down, Flags SIX Swiss Delisting	Feb. 28	MT
ObsEva Secures Temporary Moratorium Against Creditors	Jan. 31	MT
ObsEva to File for Moratorium in Geneva, Switzerland	Nov. 30	MT
ObsEva to Return Global Rights on Ebopiprant to Xoma	23-10-30	MT
ObsEva Net Loss Narrows in H1	23-09-27	MT
ObsEva SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
ObsEva Terminates Licensing Deal with Yuyuan BioScience for Oral Oxytocin Receptor	23-07-13	MT
ObsEva SA Announces Termination of Its Sub-Licensing Agreement with Yuyuan Bioscience	23-07-13	CI
SIX Group Makes Index Adjustments Following Review	23-07-11	MT
Switzerland's ObsEva Appoints Permanent CEO	23-05-02	MT
ObsEva SA announced that it expects to receive CHF 1.54 million in funding from ObsEva USA Inc.	22-12-07	CI

Chart ObsEva SA

Duration

Period

More charts

Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat womenâs reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OBSEVA SA	-83.15%	1.13M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs